TRANSGENE Reports Financial Results For First Six Months Of 2014 And Provides Update On TG4010

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG) today announced its financial results1 for the six-month period ended June 30, 2014 and provided an update on one of its lead development programs, TG4010 MUC-1 targeted cancer immunotherapy.

Help employers find you! Check out all the jobs and post your resume.